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ABSTRACT

(

A questionnaire was mailed to the third party providers (n=313)
registered with the National Council for Prescription Drug Programs
(NCPDP), State Medicaid Programs and Blue Cross plans not listed with
the NCPDP. The response rate was 41.5%. The respondents were
evaluated for their demographics (number of prescriptions processed,
number of subscribers, number of drug benefit models and type of third
party) and pre approval process (if they required the provider to obtain pre
approval, process of pre approval, time required for giving pre approval
and person responsible for obtaining the pre approval). Information was
also gathered on drug utilization review conducted on compounded
prescriptions and the reimbursement scheme for compounded
prescriptions.

(

The results of the study revealed that the majority of third party
providers do not perform any kind of drug utilization review on their
compounded prescriptions. Also most of the third party providers in the
study group did not require their provider to obtain pre approval nor did
they have a preapproved list of compounded prescriptions. Moreover
most of the respondents reimburse for drugs compounded for FDA
unapproved uses.
It appears that there is a need for the third party to reevaluate their

current reimbursement, review and coverage of compounded
prescriptions.

ii
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INTRODUCTION
(
Compounding is a pharmacist's prerogative and has always been a part of
pharmacy practice. The laws of some states include compounding in their
definition of the practice of pharmacyl. The Latin recipe Secundum artum meant
that the pharmacist would use his professional knowledge to compound drugs
into a dosage form. The pharmacist was well aware of the physical and chemical
properties and could make the dosage form providing a therapeutic effect.
Secundum arturn empowered the pharmacist to combine drugs into a
medication. Even today with the latest technological advances and growth of the
pharmaceutical industry, almost 98% of the pharmacists compound drugs
though on a relatively smaller scale2.
There are several reasons as to when and why a pharmacist may
compound drugs.
1.

Pharmacists compound drugs when they are not commercially available

in the required strength or dosage form as required for optimum patient
therapeutic activity. Usually drugs are available only in strengths and dosage
forms that provide ease of administration and optimum therapeutic effect to the
majority of patients. Thus the provider may prescribe and the pharmacist
prepare and dispense drugs needed in limited strengths or alternate dosage
forms and/ or packaging. The problem becomes acute especially in geriatric and
pediatric care. Many of the elderly have difficulty in swallowing and the
provider often must tailor the dosage form to enhance patient compliance. In the
case of pediatric medication many children are allergic to the dyes and
preservatives found in commercially available products. Hence for this patients,
the pharmacist can prepare the product free of such dyes or preservatives.

1

2.

(

Many times, for reasons of stability, a product should be prepared just

before it is dispensed. In such cases, the pharmacist compounds small quantities
of the prescription when the need arises.
3.

Another form of compounding is in the field of radioactive substances.

Nuclear pharmacists compound various radioactive substances for diagnosis,
imaging and treatment of patients.
4.

Sometimes physicians and pharmacists work together to make a product

that meets a specific patient need. At times this has led to the development of a
new dosage form that later became commercially available. Some examples are
fentanyl lozenges, minoxidil lotion and nystatin lozenges3.
5.

Home infusion therapy is the fastest growing segment of compounded

prescriptions. The number of diagnoses that can be treated at home is increasing
and so is the demand for home infusion therapy where compounding accounts
for most of the product dispensed. The following table shows the market share
of the various classes of drugs in home infusion market4.
Infusion treatment category

Percent market share

41
23
10

Antibiotic
Total parenteral nutrition
Enteral nutrition
Chemotherapy
Other

7

19

Oncologists, gastroenterologists, internal medicine specialists, general
practitioners, obstetricians/ gynecologists and pediatricians are the most
common prescribers of home infusion therapy4.
6.

The emerging field of biotechnology is projected to provide tremendous

opportunities for pharmacists to use their compounding skills. Many
biotechnology drugs have a short half lifes, are expensive and require unique
delivery systems.

2

However today this very heritage of compounding is in the midst of a
(
I

controversy. In the past few years there have been several cases where
pharmacists were clearly manufacturing under the guise of compounding. In
one such case, the FDA attempted to regulate a pharmacy that was involved in
the manufacture of more than 300,000 dosage units of albuterol sulfate and other
inhalation therapy drugs per month for 6,000 patients, most of which were
shipped by interstate commerces. Another firm was involved in the production
of liquids in a 30 liter tank in a building that did not appear to be a pharmacy.
This 'pharmacy location' had a shipping area, sterile area for compounding,
mixing and filling area, a drug storage area, a billing area and two customer
services offices. All the compounded products were shipped to customers by
federal express or airborne express. There was absolutely no patient walk in
with prescription dispensing service. The customers were pharmacies, medical
supply firms and home health care facilities. This firm made its products by
diluting brand name drugs and bulk drug products5. There were cases where
the pharmacies diluted Proventil (a product of Schering laboratories),
repackaged and marketed it as Proventil. Analysis of these samples found
mislabeled or absent expiry dates and lot numbers, diluted concentrations of the
antibacterial benzalkonium chloride and samples contaminated with
pseudomonas5.
It was not only these issues concerned with the large scale manufacturing

operations that drew the attention of FDA but also some of the practices and
issues surrounding the traditional compounding of products. There were cases
where the patients were affected by the medication compounded by the
pharmacist. One such example of injury to the patients resulting from
compounded products occurred in 1990 in Pittsburgh, PA. Several patients
suffered from eye infection from the indomethacin eye drops that had been

3

compounded by a pharmacist6. Two had to undergo surgical removal of the eye.
(

In Nebraska some patients died after receiving microbially infected surgical

solutions made by a hospital pharmacy6.
All such instances were viewed by the FDA from a public health
perspective. Until recently the number of such cases concerned with
compounding that came to the FDA notice were few and relatively less
significant8. Also the practice of pharmacy was mainly left to the domain of the
state boards of pharmacy. However lately there has been an increase in the
number of pharmacies involved in the large scale manufacturing of drugs
providing large quantities of adulterated, misbranded or unapproved drugs. In
other words these pharmacies were clearly violating the Food, Drug and
Cosmetic acts. These pharmacies were operating as a pharmaceutical companies
except unlike the latter they did not conform to FDA regulation. In view of
public health and safety and efficacy of products, the FDA issued an FDA
Compliance Policy Guide 7132.16 (CPG) in March 19929. The CPG discusses the
factors that the agency will take into consideration while deciding whether a
pharmacy has extended beyond the scope of traditional compounding and
assumed the role of a manufacturer. According to these guidelines FDA action
will take place in case the pharmacists resorted to the following activities.
1.

Soliciting business (e.g. promoting, advertising, or using sales persons) to
compound specific drug products, product classes, or therapeutic classes
of drug products.

2.

Compounding, regularly, or in inordinate amounts, drug products that
are commercially available in the marketplace and that are essentially
generic copies of commercially available, FDA approved products.

3.

Receiving, storing, or using drug substances without first obtaining
written assurance from the supplier that each lot of the drug substance
has been made in an FDA approved facility.

4

4.

Receiving, storing or using drug components not guaranteed or otherwise
determined to meet official compendia requirements.

5.

Using commercial scale manufacturing or testing equipment for
compounding drug products.

6.

Compounding inordinate amounts of drugs in anticipation of receiving
prescriptions in relation to the amounts of drugs compounded after
receiving valid prescriptions.

7.

Offering compounded drug products at wholesale to other state licensed
persons or commercial entities for resale.

8.

Distributing inordinate amounts of compounded products out of state.

9.

Failing to operate in conformance with applicable state law regulating the
practice of pharmacy.

(

The foregoing list of factors is not intended to be exhaustive and other
factors may be appropriate for consideration in a particular case. CPG stated that
FDA recognizes that pharmacists have traditionally compounded and
manipulated reasonable quantities of drug upon receipt of a valid prescription
(i.e., an oral or written order from a practitioner licensed by state law to
administer or order the administration of the drug to an individual patient
identified by the practitioner in the course of his or her professional practice) for
an individually identified patient from a licensed practitioner. This traditional
activity was not the subject of the CPG. According to the CPG, a pharmacist can
compound in response to a valid prescription for an individual patient. Thus the
CPG was only to differentiate between compounding and manufacturing.
However the FDA officers at the local level sent warning letters to pharmacists
for whom compounding constituted only around 2% of their total pharmacy
sales7. These letters warned the pharmacists against FDA action in the event that
they resorted to compounding. The reason was that any drug compounded in
the pharmacy was a new drug and hence subject to NOA approval. This

5

contradictory stand has created confusion among the pharmacists, pharmacist

(

groups and other agencies as to whether compounding constitutes a violation of
CPG.
As part of its effort to clear the confusion prevailing over compounding
vs. manufacturing, the American Pharmaceutical Association (APhA) in
consultation with FDA and other pharmacists has defined compounding and
manufacturing.
Compounding has been defined as " the preparation, mixing, assembling,
packaging or labeling of a drug or device (1) as the result of a practitioners
prescription drug order or initiative based on the pharmacist /patient/
relationship in the course of professional practice or (2) for the purpose of, or as
incident to research, teaching, or chemical analysis and not for sale or dispensing.
Compounding also includes the preparation of drugs or devices in anticipation
of prescription drug orders based on routine, regularly observed prescribing
patterns4.
Manufacturing on the other hand is defined as the production,
preparation, propagation, conversion or processing of a drug or device either
directly or indirectly by extraction from substances of natural origin or
independent! y by means of chemical or biological synthesis and includes any
packaging or repackaging of the substances or labeling or relabeling of its
container and the promotion and marketing of such drugs or devices.
Manufacturing also includes the preparation and promotion of commercially
available products from bulk compounds for resale by pharmacies, practitioners
or other person4.
One of the largest groups of compounding pharmacists, Professional &
Patients for Customized Care (P2C2) filed a lawsuit against the federal
government and many of its agencies to block the enforcement of CPG on the

6

grounds that it violated the federal procedural law. The basic argument adopted
by P2C2 was that the CPG, adopted by the FDA as an internal guideline is
actually a substantial change in federal policy that significantly have an impact
on pharmacy practitioners, and that the policy should have been promulgated as
a formal rule with advance notice to the public to commentS. However the US.
District court ruled out that the FDA could continue to take actions against the
pharmacies based on CPG since CPG did not significantly impact the traditional
compounding of pharmacy profession. P2C2 has filed an appeal with the Fifth
Circuit Court of appeal that will be decided sometime this year since the
submission of this thesis the compounding controversy still exists.
All this confusion over compounding has raised questions regarding the
third party coverage, review and reimbursement of compounded prescriptions.
A detailed literature survey did not provide any information on the type of drug
utilization review (DUR) performed on compounded prescriptions. In fact it is
not even clear whether third party providers conduct DUR on compounded
prescriptions. DUR can be performed on all the ingredients in the prescription or
only on the active ingredient or the most costly ingredient. However the
literature does not disclose any of this information.
Second the literature does not discuss any issues pertaining to
preapproval. It remains unclear whether third party organization have a
formulary of drugs or formula that can be compounded. No information is
available as to whether providers are required to obtain pre approval before
compounding any prescription. Also it remains unknown as to who is
responsible for obtaining preapproval (physician or pharmacist or either), the
mechanics of the preapproval process (form, phones, faxes) and the time period
needed to obtain pre approval.

7

Many times a physician in the course of his practice may prescribe a drug

(

to be compounded for FDA unapproved uses. It is unclear as to whether these
prescriptions will be reimbursed by the third party. Some or most of the
compounded prescriptions may contain more than one active ingredient. As the
number of active ingredients in the prescription increases the chances of adverse
effects also increases. In the absence of any safety or efficacy studies, it remains
unclear if the third party providers restrict the number of active ingredients per
reimbursed compounded prescription.
Third, the literature does not discuss the type of reimbursement scheme
adopted by the third party for compounded prescriptions. Only five of the State
Medicaid programs specifically refer to compounded products in their
reimbursement scheme. The District of Columbia reimburses compounded
prescriptions on the basis of either allowable charges of all billable ingredients
plus dispensing fee or the providers usual charge to the publiclO. The Medicaid
program in Mississippi reimburses compounded prescriptions for topical use
only if at least one legend drug (in therapeutic amounts) is included in the
ingredientslO. Mississippi also covers compounded oral medications when all
ingredients are covered separately under their own drug codes in the formulary.
The Medicaid program of Nebraska reimburses compounded prescriptions at the
lesser value of product cost (Federal upper limit, State Maximum Allowable Cost
or EACl) plus an appropriate dispensing fee or at the usual and customary
charge to the publiclO. The Medicaid program of Pennsylvania has defined a
compounded prescription as one that is prepared at the time of dispensing and
involves the weighing of at least one ingredient that must be a legend drug in
therapeutic amountlO. The Medicaid program of West Virginia defines

1 EAC-Estimated Acquisition Cost is an estimation made by a third party, of the actual amount a pharmacy

would pay a supplier for a given product.

8

compounded prescriptions as any legend medicament requiring a combination

(

of any two or more substances to exclude normal reconstitution operationslO.
There is no information regarding the reimbursement of compounded
prescriptions under the remaining State Medicaid programs or by various
private insurance companies.
Finally no data is available on the growth or decline of compounded
prescriptions over the years. Almost all pharmacists occasionally compound
prescriptions but the contribution of these prescriptions to their total prescription
sales either in terms of volume or dollar amount remains unclear.
This study is designed to explore the issues of Drug Utilization Review,
pre approval for compounding and the reimbursement scheme. The study
focuses on the following areas:
1.

Current mode of reimbursement for compounded prescriptions
This includes the formulas of the reimbursement scheme
(e.g., EAC +dispensing fee), the number of models that reimburse
compounded prescriptions and identify factors factors( e.g., dosage, time)
affecting the reimbursement scheme.

2.

Problems with the current coverage schemes
To include documenting whether drug utilization review is performed on
compounded prescriptions and whether the insurer reimburses for FDA
approved drugs compounded for unapproved uses. In addition the study
gathered information as to whether the insurer requires their participating
pharmacies to provide compounding services and the time frame within
which the services have to be provided.

9

3.

Limitations on compounded prescriptions coveraae
To includes documenting the presence or absence of a formulary of drugs
to be compounded, requirements for preapproval of compounding drugs,
the type of preapproval process and the amount of time required for pre
approval.

10

METHODS
MEASURES

A draft questionnaire was initially developed. This consisted of 25 close
ended questions pertaining to third party coverage, review and reimbursement of
compounded prescriptions. The draft questionnaire was pretested, the panelist
being graduate pharmacy students, faculty of the Division of Applied
Pharmaceutical Sciences and third party administrators. The purpose for
pretesting was to eliminate any discrepancies that might arise in the interpretation
of these questions by the respondents. On the basis of the suggestions made by
this group, a final questionnaire was developed.
The questionnaire was mailed to the third party providers, throughout the
United States who comprised the target population. The list of their names and
addresses was obtained from the National Council for Prescription Drug
(

Programs(NCPDP), the State Medicaid programs and the Blue cross plans not
listed in the NCPDP. The study took into consideration Health Insurer
(Government, Not for Profit and For Profit), Health Maintenance Organizations,
Mail Service Prescription Company and Pharmacy Benefit Management
Company. The target population therefore composed of 313 third party
providers.
The questionnaire (see appendix B ) was divided into four sections. The
purpose of section one was to demographically describe the respondent. The
respondents were asked to identify themselves as any of the following-for profit
health insurance company, not for profit health insurance company, HMO, mail
service prescription company, pharmacy benefit management company and
Federal/State agency. Questions 2 and 3 sought to determine the number of
subscribers enrolled and the total number of prescriptions processed during the

11

(

calendar year 1993. Information was also gathered on the number of drug benefit
models administered by the respondents under the capitation, fee for service and
usual and customary reimbursement scheme. Hence section one attempts to
describe the company in terms of the number of prescriptions processed, number
of subscribers enrolled and the number of drug benefit models that in turn could
be related to the reimbursement policy and coverage of compounded
prescriptions.
The purpose of section two is three fold. First information was gathered
regarding the number of models that reimbursed compounded prescriptions.
Those respondents who did not reimburse compounded prescriptions or
reimbursed only under some of their models were asked whether they intended
to reimburse under all their models within the next two years. Questions were
directed towards gaining more information on the reimbursement formula (e.g.

(

EAC +dispensing fee) and if these formulas differ according to the dosage form
or the time required for compounding.
Second the respondents were asked whether the company had any
mechanism whereby they can identify when a drug is being compounded for
FDA unapproved uses. Also an attempt was made to determine whether the
respondents reimbursed FDA approved drugs compounded for unapproved
uses.
The final part of this section focused on the pre approval process. The
respondents were asked whether they have a pre approved list of prescriptions to
be compounded and whether they require the provider to obtain pre approval
before compounding. When pre approval is required, a series of questions
followed trying to gather more information with respect to the person responsible
for obtaining the pre approval (prescriber or pharmacist), the pre approval

(
12

process (pre approval form, faxes, computer) and the number of hours required
for pre approval.
Section three dealt with drug utilization review (DUR). The focus was to
determine whether the third party conduct DUR and the type of DUR
(retrospective, prospective or concurrent). Moreover the respondents were asked
whether they conduct DUR only on the single most costly ingredient in the
formula or on all the ingredients. Those respondents who do not currently
conduct DUR on compounded prescriptions were asked as to whether they
intended conducting it within the next two years.
The fourth and the final section of the questionnaire sought to determine
the status of compounding under the present drug benefit programs. Questions
were directed towards gaining details concerning the growth or decline of
compounded prescriptions and the contribution of compounded prescriptions
towards total prescription sales. Finally, the respondents were asked whether
they require participating pharmacists to compound drugs and provide
compounding services within a specified period of time.

PROCEDURES

A cover letter (Appendix Al) and self addressed, pre stamped envelope
accompanied each questionnaire . The questionnaire was addressed to the person
responsible for making corporate policies, usually the director of pharmacy
programs. The cover letter explained in detail the intent of the study and
requested the respondents to return the completed questionnaire within a
specified period. To avoid bias and obtain accurate information the respondents
were requested not to identify themselves. A month later, A second mailing with
the same questionnaire and cover letter (Appendix A) was conductedand only
those who had not replied were requested to return the questionnaire.
13

Mailing of the questionnaire began on 12th December 1994. The
(

deadline for the return was 15th January 1995. The follow up questionnaire was
mailed on 23rd January and the deadline for the return was 20th February.

DATA ANALYSIS
The data was analyzed using SAS version 6.06 on the IBM Mainframe
Computer System housed at the University of Rhode Island. The analysis was
carried out to document the characteristics of reimbursement pertaining to
compounded prescriptions using descriptive statistics. The main focus was on
drug utilization review, pre approval, reimbursement scheme and the status of
compounded prescriptions under the drug benefit program.
The Proc Freq was used to determine the frequencies of the variables. On
the basis of the frequencies, the pertinent variables were selected for bivariate
analysis. The independent variables were dichotomised at thier mid point, e.g
number of subscribers was dichotomised as more than 100,000 and 0-100,000. The
independent variables included the type of third party, number of prescriptions
processed, number of subscribers, number of drug benefit models and the
percentage of compounded prescriptions in terms of total prescription volume.
The dependent variables included the presence of DUR, number of ingredients on
which DUR is conducted, factors (e.g. dosage, time) affecting the reimbursement
formula, presence of a preapproved list of drugs to be compounded, whether the
third party reimburses for FDA approved drugs compounded for unapproved
uses, whether the third party require their provider to obtain pre approval before
compounding prescriptions and the growth of compounded prescriptions (in
terms of percentages) over the last two years.
Chi-square statistic was performed to measure the degree of association.
(

Three levels of association was used: highly significant with p-values less than
14

0.01, significant with p-values of 0.01-0.10 and marginally significant relationships

(

had p-values of greater than 0.10 to 0.15.
Prevalence odds ratio for the bivariate association between the
independent variable and dependent variable was calculated using the formula
(Kleinbaum 1982):
Pr OR = (# of exposed cases)*(# of unexposed non cases)
(# of exposed non cases)*(# of unexposed cases)
A 95% Confidence Interval for the odds ratio was calculated using the following
formula95% CI= Pr ORl±(l.96/X}
where Pr OR is the prevalence odds ratio and Xis the square root of the chi
square.
Dichotomization of variables
Independent variables

1.

Type of third party

O=For profit health insurance company
1-Not for profit health insurance company

2.

Number of prescriptons processed
in the calendar year 1993

O=More than 500,000
1=0-500 ,000

3.

Number of subscribers enrolled
in the calendar year 1993

O=More than 100,000
1=0-100,000

4.

Percentage of compounded prescriptions
in terms of total prescription volume

O=Greater than 1%
1=0-1%

Dependent variables
1.

Require the pharmacist to differentiate between
compounded and non compounded prescriptions

15

O=Yes
l=No

(

2.

Presence of a preapproved list of prescriptions
to be compounded

O=Yes
l=No

3.

Able to identify when an FDA approved drug
is compounded for unapproved uses

O=Yes
l=No

4.

Reimburse FDA approved drug compounded
for unapproved uses

O=Yes
l=No

5.

Require the provider to obtain preapproval
before they can compound

O=Yes
l=No

6.

Factors affecting the reimbursement of
compounded prescriptions

O=Dosage or time
l=None

7.

Conduct drug utilization review
on compounded prescriptions

O=Yes
l=No

8.

Allow more than one active ingredient
per compounded prescription

O=Yes
l=No

9.

Growth of compounded prescriptions
over the last two years

O=lncreased
l=Decreased

10.

Require all participating pharmacies
to compound prescriptions

O=Yes
l=No

11.

Require the pharmacies to provide compounding
services within a reasonable period of time

O=Yes
l=No

16

RESULTS
I

A total of 313 questionnaires (Appendix A) were mailed to the third party
providers registered with the National Council for Prescription Drug Programs
(NCPDP), the state Medicaid programs and the Blue Cross plans. A total of 142
questionnaires were returned. Of these 6 were undeliverable. 5 were either not
answered or incomplete. 1 was received after the cut off-date. Hence only 130
questionnaires could be used for the final analysis (41.53%).

A.

CHARACTERISTICS OF THE THIRD PARTY COVERAGE, REVIEW
AND REIMBURSEMENT OF COMPOUNDED PRESCRIPTIONS

1.

Demographics of third party providers
Table 1 provides the summary of the demographics of third party

providers. A total of 130 third party providers responded to the survey.
Pharmacy Benefit Management Companies dominated the study group
representing 31.0% of the study group followed by the Federal/State agencies
that accounted for 27.1 %. 11.6% of the respondents were Health Maintenance
Organizations while 4.7% constituted Mail Service Prescription Companies. For
Profit Health Insurance Companies represented 19.4% of the study group and
Not For Profit Health Insurance Companies the remaining 6.2%.
About 63% of the third party providers processed more than 1,000,000
prescriptions in the calendar year 1993. 16.5% of the respondents had 500,0001,000,000 prescriptions while 9.4% processed between 0-50,000 prescriptions
during the same period. 50,000-100,000 and 100,000-500,000 prescriptions were
processed by 3.1 % and 7.9% of the third party providers in the study group
respectively.
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37.5% of the third party providers had 100,000-500,000 subscribers
enrolled in the calendar year 1993. More than 1,000,000 subscribers were
enrolled by 22.7% of the respondents. Around 10,000-50,000 and 50,000-100,000
subscribers were enrolled by 5.5% and 11.7% of the third party providers in the
study group respectively. 1.6% of the respondents had 0-5,000 and another 1.6%
had 5,000-10,000 subscribers enrolled in the calendar year 1993. The remaining
19.5% of the third party providers in the study group had 500,000-1,000,000
subscribers.
Majority of the respondents(72.2%) had no models under the capitation
system. 4.8% of the third party providers had one, 8.7% had two and 0.8% had
three drug benefit models. 2.4% and 11.l % of the respondents revealed that they
had four and more than four models respectively under the capitation system.
14.3% of the respondents had no drug benefit plans under the fee for
service system. One, two and three drug benefit models were available under
this system in the case of 23.0%, 7.9% and 3.2% of the third party providers in the
study group respectively. 4.0% of the respondents have four models and the
remaining 47.6% had more than four models under the fee for service
reimbursement scheme.
Under the usual and customary system, 46.8% had no drug benefit
models. 13.5% had one, 9.5% had two, 1.6% had three and yet another 1.6% of
the respondents revealed that they four models under the usual and customary
reimbursement scheme.
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Table 1.

Demographic characteristics of third party

Characteristics

% Total
(n=130)

Type of third party
For profit health insurance company
Not for profit health insurance company
Health Maintenance Organization
Mail Service Prescription Company
Pharmacy Benefit Management Company
Federal/State agency

6.2
19.4

11.6
4.7
31.0

27.l

Number of prescriptions processed in 1993
0-50,000
50,000-100,000
100,000-500,000
500,000-1,000,000
More than 1,000,000

9.4
3.1
7.9
16.5
63

Number of subscribers enrolled in 1993
0-5,000
5,000-10 ,000
10,000-50,000
50,000-100,000
100,000-500,000
500,000-1,000,000
More than 1,000,000

1.6
1.6
5.5
11.7
37.5
19.5

22.7

Number of Drug Benefit Models
Capitation
None
One
Two
Three
Four
More than four

72.2

4.8
8.7
0.8
2.4

11.l

l
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Table 1.. ..continued

(
Characteristics

%Total
(n=130)

Fee for service
None
One
Two
Three
Four
More than four
Usual and customary
None
One
Two
Three
Four
More than four

14.3
23.0
7.9
3.2
4.0
47.6
46.8
13.5
9.5
1.6
1.6
27.0
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2.

PROCESS OF PREAPPROVAL

A summary of the results of the pre approval process is presented in Table 2. Of
the 130 respondents, 10.8% had a preapproved list of prescriptions to be
compounded, however the majority (89.2%) stated that they did not have a
preapproved list.
82.2% of the third parties in the study group did not require the provider
to obtain pre approval before they could compound and receive reimbursement.
17.8% required the providers to obtain pre approval. Of those that required pre
approval, 21.7% placed the responsibility on the prescriber while 47.8% required
the pharmacist to obtain pre approval. 30.4% of the third party providers
in the study group stated that they needed either the pharmacist or the prescriber
to obtain the pre approval.
The process of pre approval also varied among the respondents who have
the requirement of pre approval. 30.4% required the use of phone for obtaining
pre approval. Pre approval form and computer were used by 8.7% and 4.3% of
the respondents respectively. 8.7% did not restrict the process of pre approval.
The providers could choose any of the processes. 4.3% each of the third parties
required the provider to choose between form and fax or phone and fax or
computer and phone or phone, fax and computer.
43.5% of the respondents revealed that they gave approval immediately.
About 34.8% stated that the process usually takes less than 24 hours while 21.7%
replied that it took about 48 hours.
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Table 2

Summary of the process of pre approval

Pre approval

% Total
(n=130)

Presence of a preapproved list of prescriptions
to be compounded
Yes
No

89.2

Require the provider to obtain pre approyal
before compounding the prescription
Yes
No

17.8
82.2

Person responsible for obtaining pre approval
Prescriber
Pharmacist
Either pharmacist or prescriber
Process of pre approval
Form
computer
Phone

10.8

21.7
47.8
30.4

8.7

4.3
30.4

Any
Form or fax
Phone or fax
Phone or computer
Phone or fax or computer
Form or computer or phone
Form or phone or fax

8.7
4.3

4.3
4.3

4.3
13.0

17.4

Number of hours to obtain pre approval
Immediate! y
Within 24 hours
Within 48 hours
More than 48 hours

(
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43.5
34.8
21.7
0.00

3.

DRUG UTILIZATION REVIEW

(
Table 3 shows the results of the Drug Utilization Review. 57.4% of the third
party providers in the study group currently conduct drug utilization review on
compounded prescriptions while the remaining 42.6% do not. Of those who do
not perform DUR about 25% planned to do it in the next year, 8.9% in the next
two years and 3.6% after two years. 57.1 % of the third party who do not conduct
DUR has no intention of conducting it even in future while 5.4% are still
undecided as to whether they should perform DUR on compounded
prescriptions.
30.1 % conduct retrospectively followed by 26.0% who conduct either of
the three types. Concurrent review is performed by 9.6% and prospective by
5.5% of the respondents. About 8.2% of the respondents revealed that they
conduct either prospective or retrospective studies while 1.4% stated that they
perform either prospective or concurrent DUR.
52.1 % of the third party providers in the study group stated that they
conduct DUR on all the ingredients in the prescription. However 41.1 % of the
respondents revealed that only the single costly ingredient in the prescription is
taken into consideration for performing DUR. The remaining 6.8% of the
respondents conduct DUR on either the costly ingredient or on all the
ingredients.
With reference to the number of active ingredients in the compounded
prescriptions about 94.5% did not place any restrictions on the number of active
ingredients to be included in the compounded prescriptions. However 5.5% of
the respondents did not allow the provider to compound more than one active
ingredient per prescription.
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Table 3

Process of Drug Utilization Review

Drug Utilization Review

% Total
(n=130)

Conduct Drug Utilization Review on
compounded prescriptions
Yes
No

57.4
42.6

Intend to conduct DUR on compounded
prescriptions in future
Yes, within one year
Yes, within two years
Yes, after two years
No
Don't.know
Type of Drug Utilization Review
Prospective
Concurrent
Retrospective
Concurrent & Retrospective
Prospective & Retrospective
Prospective & Concurrent
All three types

25.0
8.9

3.6
57.l
5.4

5.5

9.6
30.1
19.2
8.2
1.4
26.0

Number of ingredients on which
DUR is performed
Only on the single costly ingredient
On all the ingredients
Either on costly or on all the ingredients
Allow more than one active ingredient
per compounded prescription
Yes
No
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41.1
52.1

6.8

94.5
5.5

Status of compounded prescriptions
(

The status of compounded prescriptions under the drug benefit models is
presented in table 4. 46.9% of the respondents were not aware if there was an
increase or decrease in compounded prescriptions. 16.9% felt that it had
remained the same. An increase of 0-5% was reported by 14.6% and 7.69% of the
respondents stated that compounded prescriptions had increased by 6-10%.
Another 3.85% of the respondents was of the opinion that compounded
prescriptions may have increased by 11-15% while an increase of 16-20% was felt
by 1.54% of the respondents.
Of the third party providers who reported a decline in compounded
prescriptions, 4.61 % stated that there was a decline of 6-10% while a decline of 05% was reported by 0.77% of the third party providers in the study group. 1.54%
of the respondents revealed a decline of 16-20%.
About 66.4 % reported that compounded prescriptions accounted for less
than 1% of their total prescription volume. 24% of the respondents revealed that
it made up 1-5% of their total prescription volume. Compounded prescriptions
represented about 6-10% of the prescription volume in 1.6% of the respondents
drug benefit programs. 8% of the third party providers in the study were not
aware of the contribution of compounded prescriptions to their total prescription
volume.
34.6% of the respondents required their participating pharmacies to
compound prescriptions under all their drug benefit models while 1.5% required
it only under some models. 63.8% did not place any emphasis on providing
compounding services by their pharmacies.
21.5% of the third party providers in the study allowed a time limit on 24
hours to their pharmacies for providing compounding services. A time period of
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more than 24 hours was acceptable to 3.8% of the respondents. 74.6% of the third

(

party providers in the study group revealed that they did not place any time
restrictions on their pharmacies for providing compounding services.
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Table 4

Status of compounded prescriptions

Variable

% Total
(n=130)

Percentage of compounded prescriptions
in terms of total prescription volume
Less than 1%
1-5%
6-10%
Don't know
Growth in compounded prescriptions
Increased by 0-5%
Increased by 6-10%
Increased by 11-15%
Increased by 16-20%
Increased but don't
know by how much
Decreased by 0-5%
Decreased by 6-10%
Decreased by 16-20%
Remained the same
Don't know

66.4
24.0
1.6

8.0
14.62
7.69
3.85
1.54

1.54
0.77

4.61
1.54

16.92
46.92

Require all participating pharmacies
to provide compounding services
Yes, in all the models
Yes, in some of the models
No

34.6
1.5
63.8

Require the pharmacies to provide services
within a reasonable period of time
Yes, within 24 hours
Yes, more than 24 hours
No
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21.5
3.8

74.6
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Reimbursement scheme
A summary of the reimbursement scheme is given in table 5.
All the third party providers in the study reimbursed compounded prescriptions
under their capitation scheme. 88% of them reimbursed under all the models
while 11.43% reimbursed under some of the models. Of the respondents who
offered fee for service scheme, 94.39% reimbursed compounded prescriptions
under all the models while 4.67% reimbursed under some of their models. The
remaining 0.93% did not reimburse compounded prescriptions under any of
their fee for service models. Regarding the third party providers who had the
usual and customary models, 86.57% reimbursed under all their models while
7.46% reimbursed only under some of their models. 6.89% of the respondents
did not reimburse under any of their usual and customary models.

(

The majority of the respondents 82.2% required their provider to
differentiate between compounded and non compounded prescriptions for
reimbursement. The remaining 17.8% of the third party providers in the study
revealed that they did not require the pharmacist to specify the type of
prescription.
31.5% of the respondents stated that they were not able to identify when
an FDA approved drug is compounded for unapproved uses. 68.5% of the third
party providers could determine when an FDA approved drug was
compounded for unapproved uses.
Regarding the reimbursement for FDA unapproved uses, 50.4% of the
respondents stated that they reimburse an FDA approved drug compounded for
unapproved uses. 49.6% revealed that they did not reimburse for the same.
Dosage of the compounded prescription was taken into consideration for
reimbursement by 4.0% of the respondents. 8.0% of the third party in the study
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group took time required for compounding into account while 10.4% took both
(

time and dosage into account while reimbursing compounded prescriptions.
77.6% of the third party providers revealed that none of these factors affected
their reimbursement formula.
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Table 5

Summary of the reimbursement scheme

Reimbursement scheme

% Total
(n=130)

Number of models that reimburse
compounded prescriptions
Capitation
All
Some
None

88.0
11.43
0.00

Fee for service
94.39
4.67
0.93

All

Some
None
Usual and customary

86.57
7.46
6.89

All

Some
None
Require the provider to differentiate between
compounded and non compounded prescriptions
Yes
No

82.2

17.8

Able to identify when an FDA approved drug
is compounded for unapproved uses
Yes
No

31.5
68.5

Reimburse FDA approved drugs compounded
for unapproved uses
Yes
No

50.4
49.6

Factors affecting the reimbursement scheme
Dosage
Time required for compounding
Both dosage and time
None

(
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4.0
8.0
5.6
82.4

The Bivariate Relationship Between the Independent Variables and If the
Third Party Require the Provider to Differentiate Between Compounded and
Non Compounded Prescriptions for Reimbursement

The analysis for the relationship between the third party requirement to
differentiate between compounded and non compounded prescriptions and the
independent variables are shown in table 6. No statistically significant
association was found among any of the variables. The chi-square value ranged
from 0.002 (number of drug benefit models) to 1.411 (type of third party).
Table 6

Summary of the bivariate association of the independent
variables and if the third party requires their providers to
differentiate between compounded and non compounded
prescriptions for reimbursement.

Variable
(

p-value

Type of third party
(For profit vs. Not For Profit)

1.411

0.235

Number of prescriptions
(>500,000 vs. <500,000)

0.179

0.672

Number of subscribers
(>100,000 vs. <100,000)

0.074

0.785

Number of drug benefit models
(>8 vs. <8)

0.002

0.965

Percentage of compounded prescriptions
in terms of total prescription dollars
(~1 vs. <1)

0.405

0.525
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Bivariate Association Between The Independent Variables and if the Third
Party have a Preapproyed List of Prescriptions to be Compounded
The analysis for the bivariate association for the presence of a
preapproved list of prescriptions to be compounded is presented in table 7 . The
variable , number of drug benefit models and type of third party were the only
statistically significant variables. The prevalence odds ratio for this variables
were 3.17 and 0.35 respectively. One of the variables, percentage of
compounded prescriptions had cells too small to count, i.e., there was only one
respondent in a particular cell. The remaining variables had Chi-squares 0.629
(number of prescriptions) and 0.068 (number of subscribers)
Table 7

Summary of the bivariate association of the independent
variables and presence of a preapproved list of prescriptions to
be compounded

x2

p-value

Pr OR

Type of third party
(For Profit vs. Not For Profit)

3.317

0.069

0.35

Number of prescriptions
(>500,000 vs. <500,000)

0.629

0.428

Number of subscribers
(>100,000 vs. <100,000)

0.068

0.795

Number of drug benefit models
(>8 vs. <8)

4.100

0.043

Variable

Percentage of compounded prescriptions
in terms of total prescription dollars
(~1 vs. <1)
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3.17

95%CI

1.037,9.68

CELLS TOO SMALL TO COUNT
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The Bivariate Relationship Between the Independent Variables and if the
Third Party can Identify when an FDA Approved Drug is Compounded for
Unapproved Uses
The variables, number of prescriptions and number of subscribers did not
reveal any statistically significant association with Chi-square values of 0.011 and
1.007 respectively. The variables, number of drug benefit models (X2=2.273,
p=0.132) and the type of third party (X2=2.294, p=0.13) showed a significant
association with prevalence odds ratio of 1.78 and 0.56 respectively. (Table 8)
Table 8

Summary of the bivariate association between the independent
variables and if the third party can identify when an FDA
approved drug is compounded for unapproved uses
p-yalue

Variable
Type of third party
(For Profit vs. Not For Profit)

2.294

0.130

Number of prescriptions
(>500,000 vs. <500,000)

0.011

0.916

Number of subscribers
(>100,000 vs.< 100,000)

1.007

0.316

Number of drug benefit models
(>8 vs. <8)

2.273

0.132

% of compounded prescriptions in
terms of total prescription dollars
(~1 vs. <1)

0.192

0.662

(
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PrOR

95%CI

0.56

0.265,1.183

1.78

0.843, 3.766
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The Bivariate Association Between the Independent Variables and if the Third
Party Reimburse for FDA Approved Drug Compounded for Unapproved Uses.

The analysis for the bivariate association between the independent
variables and reimbursement for FDA approved drug compounded for
unapproved uses as the dependent variable is presented in Table 9 . None of
the variables showed any statistically significant association. The Chi-square
value ranged from 0.034 (number of prescriptions) to 1.716 (percentage of
compounded prescriptions).
Table 9

Summary of the bivariate association between the independent
variables and if the third party reimburse for FDA approved
drugs compounded for unapproved uses

Variable

p-value

Type of third party
(For Profit vs. Not For Profit)

0.626

0.429

Number of prescriptions
(>500,000 vs. <500,000)

0.034

0.854

Number of subscribers
(>100,000 vs. <100,000)

1.556

0.212

Number of drug benefit models
(>8 vs. <8)

0.949

0.330

Percentage of compounded prescriptions
in terms of total prescription dollars
(~1 vs. <1)

1.716

0.190

(
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The Bivariate Association Between the Independent Variables and if the Third
Party Require the Provider to obtain Pre approval before they can compound
and receive reimbursement
The analysis for the association between whether the third party require their
providers to obtain pre approval before they can compound and receive
reimbursement and the independent variables is found in Table 10 . The
variables, number of prescriptions processed in the calendar year 1993 (X2=4.S39,
p=0.033) number of subscribers enrolled during the same period (X2=2.087,
p=0.149) and the type of third party (X2=2.374, p=0.098) showed statistically
significant association. The prevalence odds ratio associated with these variables
were 0.342, 0.473 and 0.466 respectively.
The summary of the analysis is presented in table 10.
Table 10

f

Summary of the bivariate association between independent
variables and if the third party require the provider to obtain
pre approval

Variable

x2

p-value

Pr OR

95%CI
0.188,1.15

Type of third party
(For Profit vs. Not For Profit)

2.734

0.098

0.466

Number of prescriptions
(>500,000 vs. <500,000)

4.539

0.033

0.342

0.12,0.918

Number of subscribers
(>100,000 vs. <100,000)

2.087

0.149

0.473

0.17,1.305

Number of drug benefit models
(>8 vs. <8)

0.261

0.610

% of compounded prescriptions in
terms of total prescription dollars
(Ll vs. <1)

1.620

0.203

(
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The Bivariate Association Between the Independent Variables and if the
Reimbursement Scheme differ based On Dosage. Time Required For
Compounding or other factors.
The analysis for the relationship between the factors affecting the
reimbursement formula and the independent variables is presented in table 11.
The analysis did not reveal any statistically significant variables. The Chi-square
value was 1.895 for the variable, number of prescriptions, 1.32 for the number of
subscribers and 0.188 for the number of drug benefit models. The variable
percentage of compounded prescriptions had cells too small to count.

(
I

Table 11

Summary of the bivariate association between independent
variables and factors affecting the reimbursement scheme

Variable

p-yalue

Type of third party
(For Profit vs. Not For Profit)

0.083

0.773

Number of prescriptions
(>500,000 vs. <500,000)

1.895

0.169

Number of subscribers
(>100,000 vs. <100,000)

1.32

0.251

Number of drug benefit models
(>8 vs. <8)

0.188

0.665

Percentage of compounded prescriptions
in terms of total prescription dollars
(~1 vs. <1)

CELLS TOO SMALL TO COUNT
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The Bivariate Association Between the Independent variables and if the Third
Party Conduct Drug Utilization Review on Compounded Prescriptions
The analysis for the bivariate association between the presence/ absence of
DUR and the independent variables revealed statistically significant association
between the type of third party (X2=4.070, p=0.044) and the dependent variable.
The Chi-square value for the variables ranged from 0.076 (percentage of
compounded prescriptions) to 1.939 (number of prescriptions). The summary of
the analysis is shown in table 12.
Table 12

Summary of the bivariate association between the independent
variables and if the third party conduct Drug Utilization Review
x2

Variables

f

I

p-value

Pr OR

Type of third party
(For Profit vs. Not For Profit)

4.070

0.044 0.4722

Number of prescriptions
(>500,000 vs. <500,000)

1.939

0.164

Number of subscribers
(>100,000 vs. <100,000)

0.261

0.610

Number of drug benefit models
(>8 vs. <8)

0.712

0.399

Percentage of compounded prescriptions
in terms of total prescription dollars
(2::.1 % vs. <1 %)

0.076

0.782
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95%CI
0.97,2.27
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The Bivariate Association Between the Independent Variables and if the Third
Party Allow More than one Active Ingredient Per Compounded Prescription
The analysis for the association between the number of ingredients per
compounded prescription as the dependent variable and the independent
variables is given in table 13. No statistically significant association was found
for the variables number of prescriptions (X2=0.189) and the number of
subscribers (X2=0.181). The variable type of third party had an odds ratio of 3.8.
The variable number of drug benefit models also showed significant association
with Chi-square as 3.417 and a p-value of 0.065. The prevalence odds ratio for
this variable was 0.228. The variable percentage of compounded prescriptions
had cells too small to count.
Table 13

(

Summary of the bivariate association between the independent
variables and if the third party allow more than one active
ingredient per compounded prescription
p-yalue Pr OR

variables
Type of third party
(For Profit vs. Not For Profit)

2.73

Number of prescriptions
(>500,000 vs. <500,000)

0.189

0.663

Number of subscribers
(>100,000 vs. <100,000)

0.181

0.671

Number of drug benefit models
(>8 vs. <8)

3.417

0.065

% of compounded prescriptions in

0.099

95%CI

3.8

0.78,18.5

0.228

0.047,1.09

CELLS TOO SMALL TO COUNT

terms of total prescription dollars
(2:1 vs. <1)
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The Bivariate Association Between the Independent variables and the Third
Party Perception about the Growth of Compounded Prescriptions Over the
Last Two Years
The analysis revealed statistically significant relationship between the
dependent variable and the number of drug benefit models (X2=5.745, pvalue=0.017). The prevalence odds ratio was 2.553. The other three variables
had Chi-square values ranging from 0.007(type of third party) 4.076 (number of
prescriptions).
Table 14

Summary of the bivariate association between the independent
variables and their knowledge about the growth of compounded
prescriptions over the last two years
p-yalue

variable
Type of third party
(For Profit vs. Not For Profit)

0.007

0.933

Number of prescriptions
(>500,000 vs. <500,000)

4.076

0.043

Number of subscribers
(>100,000 vs. <100,000)

1.438

0.23

Number of drug benefit models
(>8 vs. <8)

5.745

0.017

% of compounded prescriptions in
terms of prescription dollars
(~1 vs. <1

0.359

0.549
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Pr OR

2.553

95% CI

1.185,5.495
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The Bivariate Association Between the Independent Variables and if the Third
Party Require their Participating Pharmacies to Provide Compounding
Services.
The analysis for the relationship between the requirement for the
pharmacies to provide compounding services and the independent variables is
presented in table 15. The analysis revealed significant association for the
variable type of third party (X=4.085, p=0.043) with prevalence odds ratio of
0.472. The Chi-square values for the other independent variables ranged from
0.062 (number of subscribers) to 1.164 (number of prescriptions).
Table 15

Summary of bivariate association between the independent
variables and if the third party require their participating
pharmacies to provide compounding services.

variable

x2

Type of third party
(For Profit vs. Not For Profit)

p-value

Pr OR

95% CI

4.085

0.043

0.472

0.228,0.977

Number of prescriptions
(>500,000 vs. <500,000)

1.164

0.281

Number of subscribers
(>100,000 vs. <100,000)

0.062

0.804

Number of drug benefit models
(>8 vs. <8)

0.338

0.561

% of compounded prescriptions in
terms of total prescription dollars
(~1 vs. <1)

1.162

0.281

(
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The Bivariate Association Between the Independent Variables and if the Third
Party Require their Pharmacists to Provide Compounding Services Within a
Specified Period.
The analysis did not showany significant association with the dependent
variable. The Chi-square values were 1.256 (number of subscribers), 0.726
(number of subscribers), 1.576 (number of drug benefit models) and 1.233 for the
type of third party. The variable percentage of compounded prescriptions had
cells too small to count i.e., one of the cells had one respondent. The summary of
the analysis is shown in Table 16.
Table 16

{

Summary of bivariate association between the independent
variables and if the third party require their pharmacists to
provide compounding services within a specified time period

x2

p-yalue

Type of third party
(For Profit vs. Not For Profit)

1.233

0.267

Number of prescriptions
(>500,000 vs. <500,000)

0.246

0.620

Number of subscribers
(>100,000 vs. <100,000)

0.268

0.605

Number of drug benefit models
(>8 vs. <8)

1.576

0.209

variables

% of compounded prescriptions in CELLS TOO SMALL TO COUNT

terms of total prescription dollars
(Ll vs. <1)

(
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DISCUSSION

Table 1 showing the demographic characteristics reveal that the majority
(72.7%) of third parties do not have any models under the capitation system.
There seems to be a general favor for fee for service and the usual and customary
models. In the capitation models the pharmacy receives a set dollar amount per
person per time period for providing the needed services to that person for that
time period. However the pharmacy has to assume some finanacial risk inherent
in the capitation system and hence the pharmacies often resists the capitation
models. The third party should have sufficient market strength and market
penetration if they want to increase their capitation models. The fee for service
models on the other hand are better understood and accepted by both the third
party and the pharmacy. Hence there may be less models under the capitated
system and a general favor for the fee for service or usual and customary models.
89.2% of the respondents in this study do not have a preapproved list.
(Table 2). 82.2% do not require providers to obtain pre approval. Only 4.65% of
the third parties in the study group had both a preapproved list and required
providers to obtain pre approval before compounding. 75.97% did not have a
preapproved list and did not require providers to obtain pre approval. The
remaining respondents either had a preapproved list or required pre approval but
not both. These results are important because no safety or efficacy studies have
been conducted on the compounded prescriptions. The prescribers during their
course of medical practice may write a prescription that they feel might provide
optimum therapeutic effect for the patient. Also the pharmacists based on
stability, drug interactions and therapeutic effect of drugs will compound the
prescriptions. It is possible that there may be errors while calculating the quantity

(

of drug needed, the uses for which it is to be compounded and the interaction
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among the ingredients in the formula. The results of this study show that without
any pre approval requirement or any pre approval process as is the case with the
majority of the third party (75.97%) there may be no check on what and why the
prescription is being compounded. There are no studies that deal specifically
with the errors (e.g miscalculation of ingredients, weighing out the wrong
quantity of active ingredient) made while compounding prescriptions. In the
absence of these studies it is difficult to determine the magnitude of the
seriousness of a situation where there is no preapproved list or any pre approval
requirement. However based on studies that deal with errors (mislabeling, wrong
dose) made by the pharmacist while dispensing non compounded prescriptions
(Guernsey B.G &et al) one might say that there is a distinct likelihood that some or
many kinds of errors in compounding prescriptions might be taking place . This
is important from the standpoint of saving dollars by not only paying for
unnecessarily compounded prescriptions but also from the perspective of safety
of the patient. This raises the issue of both quality of care and cost benefit.
The processes of pre approval also vary greatly among the respondents as
can be seen from the results shown in Table 2. Majority of them use the phone for
the pre approval. A proportion of the third party providers still uses a pre
approval form. This raises the question of the number of hours it takes to obtain
the pre approval and consequently the number of hours the patient has to wait
before receiving the medication. Only 43.5% of the third party give approval
immediately. 34.8% and 21.7% of the respondents require 24 and 48 hours
respectively to give pre approval. In this case the patient has to wait for a day or
two or more than that before receiving their medication. This issue may be
serious in some life threatening cases where medication is needed immediately.
About 42.6% of the respondents do not conduct any drug utilization

(

review on compounded prescriptions (Table 3). Among these, 57.1% have no
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intention of conducting it in future and 5.4% are still undecided. Thus it can be
said that approximately half of the third party providers in the study group do
not currently conduct drug utilization review. When this percentage is combined
with the percentage of third party providers that do not have a preapproved list
(89.2%) and do not require pre approval (82.2%) for compounding, it assumes
more importance. When a provider seeks pre approval for a compounded
prescription, the insurance company usually checks for the drug, dose and if the
drug is included in the formulary if one exists. Drug Utilization Review allows
the insurance company to focus on providers who are overprescribing, identify
problems with the quality of care, a potential drug abuse problem or problems
with compliance with medical treatment on the part of the members. The tighter
the pre approval process, the greater the insurance plans ability to manage
utilization. An approval process by itself will not automatically control utilzation
although it will have an effect.
Of those respondents who conduct a review about 30.1 % conduct
retrospective review (i.e. after the prescription has been compounded). Only 9.6%
conduct concurrent review(i.e. when the prescription is compounded). Also of
those who conduct review 41.1 % conduct only on the single costly ingredient.
This may or may not be the active ingredient in the prescriptions. Also if this is
the active ingredient there may be more active ingredients on which the review is
not performed since 94.5% of the third party allow more than one active
ingredient to be included per compounded prescription.
As the number of active ingredients in the prescription increases the
chances of adverse effects for the patients may also increase. Besides almost all of
them perform DUR only on one ingredient. Thus when you combine the number
of ingredients allowed in the prescription and the number of ingredients on

(

which DUR is performed the magnitude of the seriousness of the situation
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increases. For example in the case of compounded progesterone suppositories it
makes no difference on the number of ingredients on which DUR is performed
since it contains only one active ingredient progesterone. However in the case of
a compounded prescription containing benadryl and nystatin it makes a
difference as to number of ingredients on which DUR is performed.
Third party providers usually clssify prescriptions either by therapeutic
class or by individual drugs for conducting DUR. Since compounded
prescriptions forms a small portion either as a class or as drugs they are spread
over the entire category. Under this situation (if at all) the third party conduct
retrospective DUR they cannot avoid the errors that has already been made while
compounding the prescription because the review is conducted only after the
prescription has been prepared and dispensed. Thus the very purpose for which
DUR is conducted viz. patient safety and cutting down unnecessary costs is not
(

served.
Almost all the models reimburse compounded prescriptions (Table 5).
However 68.5% of the third party cannot identify when a drug is compounded for
unapproved uses. It is quite likely that a number of these prescriptions might be
compounded for some uses for which an FDA approval has not been obtained.
Besides 50.4% of the third party reimburse FDA approved drugs compounded for
unapproved uses. This does not check the compounding of drugs for
unapproved uses.
Results of the study show that the third parties do not consider dosage
form or the time required for compounding into consideration while reimbursing
the pharmacists (Table 5). A pharmacist who compound suppositories (consume
more time and is difficult to prepare) may be paid the same as a pharmacist who
compounds solutions. This may lead to some pharmacies deciding not to
compound prescriptions or to compound only selective prescriptions.
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Only 16.2% of the respondents felt that the number of compounded
prescriptions have remained the same (Table 5). 46.92% were not even aware of
the growth of compounded prescriptions. Almost 25% of the respondents felt
that there was an increase in compounded prescriptions. About 5% felt that there
was a decrease. The difference in response maybe due to the fact that
compounded prescriptions constitutes only a small proportion of the total
prescription volume and as such is considered to play a negligible part in the
drug benefit programs. This can be concluded from the results of the percentage
of compounded prescriptions in terms of total prescription dollars. A majority of
the third party providers (66.4%) stated that compounded prescriptions only
made up less than 1% of their prescription dollars. 24% said that it made up 1-5%
of their prescription dollars. When the figure of about two billion prescriptions
dispensed per year in community pharmacies converted to its dollar value it
(

assumes more importance.
The results of the bivariate analysis revealed that the variable, number of
drug benefit models is associated with some of the dependent variables. There
seems to be a positive association between the number of drug benefit models and
the presence of preapproved list. The prevalence odds ratio of 3.17 indicates that
third party with drug benefit models greater than eight are three times more
likely to have a preapproved list than those with relatively less number of models.
Those with higher number of models (>8) are also 1.78 times more likely to
identify when an FDA approved drug is compounded for unapproved FDA uses.
However it is important to note that the confidence interval includes one which
indicates that there may or may not be an association. Besides there seems to be
an association between the number of drug benefit models and if the third parties
allow more than one ingredient per compounded prescription. Third parties with

(

more drug benefit models are only one fifth times more likely to allow more than
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one ingredient per compounded prescription. The inclusion of one in the
confidence interval makes it difficult to draw any definite conclusion regarding
the association. The third party providers with more drug benefit models are also
2.553 times more likely to be aware of the growth of compounded prescriptions
compared to those with relatively less number of models. The reason for this
maybe that as the number of drug benefit models increases there is a high
likelihood that these plans have better management. The presence of
sophisticated controls also increase as the number of plans increases.
There results of the study also revealed an association between the
variables, number of prescriptions processed, number of subscribers enrolled
and the requirement for preapproval. Third party with prescriptions greater than
500,000 are one third times likely to require preapproval and those with more
than 100,000 subscribers are one half times more likely to have the requirement
for preapproval compared to those with relatively lesser number of prescriptions
and subscribers. The reason for this is that with the increase in the number of
prescriptions there maybe a simultaneous increase in the number of compounded
prescriptions also. The third party providers who already consider compounded
prescriptions to be an insignificant part of their prescription volume and are not
aware of the dollar value do not want to expend time and money on the process
of preapproval. For those with fewer compounded prescriptions the time and
money spent on the preapproval process may be neglible.
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CONCLUSIONS
The study of the reimbursement of the compounded prescriptions
examined several factors related to the reimbursement, review and drug
utilization review on compounded prescriptions.
The respondents represented a mix of For Profit Health Insurance
Companies, Not For Profit Health Insurance Companies, Health Maintenance
Organization, Mail Service Prescription Companies, Pharmacy Benefit
Management Companies and Federal/State agencies with varying number of
subscribers , prescriptions processed and drug benefit models. The respondents
were selected on a national level and hence the results of this study are
generalizable to the third party providers throughout U.S.
The study revealed that the majority of the third party providers do not
have a preapproved list of compounded prescriptions nor do they require their
provider to obtain preapproval. In addition most of them cannot identify when
an FDA approved drug is compounded for unapproved uses and almost half of
them reimburse for this process. Moreover the third party providers do not
conduct drug utilization review on compounded prescriptions. Also among those
who conduct the review perform it only on the single costly ingredient and not
on all the ingredients. Based on the results of this study, one can conclude that
currently there appears to be no consistent check by the third party on how the
prescriptions are compounded by the prescriber or the pharmacist.
It is clear from this study that there is a need for the third party to

re evaluate their current coverage, review and reimbursement of compounded
prescriptions. This study has revealed that there are several areas that need
additional study. With the introduction of the NCPDP Telecommunication
Standard Format Version 3.2 it is now relatively easy to conduct concurrent DUR
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and DUR on all the ingredients. However cost benefit analysis studies need to be

(

conducted to evaluate the impact of installing version 3.2 for conducting
concurrent review, requiring pre approval and conducting DUR on all the
ingredients . There is also the need to perform studies to determine the extent of
errors made while compounding the prescriptions.
Majority of the third party providers currently do not require all pharmacies to
provide compounding services. The third party can assure that atleast one of their
participating pharmacy provide the services. Also a provision should be made to
provide compounding services within a reasonable period of time.
The rapidly growing segment of the elderly population and the field of
biotechnology may lead to an increase in the number of prescriptions
compounded in future. Clearly there is a need for the third parties to reevaluate
their current coverage, review and reimbursement of compounded prescriptions.

(
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APPENDIX

. UNIVERSITY OF
RHODE ISLAND

Al

December 12,1994
Dear Sir or Madam,
The enclosed survey is an attempt to delermine trurd party coverage
policy and management of compounded prescriptions. Specific areas such as drug
utilization review, preapproval and reimbursement scheme are included in this survey. The
survey is part of my thesis project towards my Master of Sciences in Pharmacy
Administration. You are assured of anonymity since nowhere in this survey have I
requested you to identify yourself. I would be very happy if you could return the
questionnaire by 15th January 1995 in the enclosed self addressed prestamped envelope .
.Your responses and opinions will be appreciated. If you have any
questions or su.ggesrionsplease feel free to contact me at 401-792-2789 or write to me.
Thank you for the time you have spent in completing my questionnaire.
Sincerely,

-:Qg~_
Renuka Nair
Graduate Srudent

cc: A .Taubman, R.Ph.,Ph.D
Major Professor
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01\'ISIOJI: OF rHARMACOErlDEMIOLOGY Al'D ADMINISTRATIVE SCIENCES, COLLEGE OF rHAR\.IACY
Kingston. Rhode Island 02881-0809
rhon~ : ~01-792- 2789

Fax: 401-792-2i81
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UNIVERSITY OF
RHODE ISLA.ND

A

January 23, 1995

Dear Sir or Madam,
The enclosed survey is a follow up of my earlier questionnaire that
was mailed to you in December 1994. This survey is an attempt to determine third party
coverage policy and management of compounded prescriptions. Specific areas such as
drug utilization review, pre approval and reimbursement scheme are included in this
survey. The survey is part of my thesis project towards my Master of Sciences in
Pharmacy Administration.

If for some reasons you were unable to return the

earlier queiotionnaire, I

would appreciate if you will fill this out and return

it by 20th February 1995 in the enclosed self addressed pre stamped
envelope. If you have already mailed the previous questionnaire please do
not return this again. You are assured of anonymity since nowhere in this survey
have I requested you to identify yourself.
Your responses and opinions wil) be appreciated. lf you have any questions or
suggestions please feel free to cont.act me at 401-792-2789 or write to me_
Thank you for the time you have spent in completing my questionnaire.
Sincerely.

~e.~_
Renuka Nair
Graduate Student

cc : A .Taubman. R.Ph. ,Ph.D
Major Professor

nt-1.i" i~~
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Mo.-klJJ~~
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,,-1 oppon-irr ""~"·

COLLEGE OF PHARMACY, DErARnm..T OF PHAR.\f.ACEUTICS

Kingston. Rhode hland 02881-0809
"!'hon<: 4-01 -792-2754

Fax: 40 1-792-2181
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The following list of questions pertains to reimbursement of compounded
prescriptions that might be included under your pharmacy benefit programs.
I request you to kindly fill out the questionnaire and return it in the enclosed self
addressed envelope. If you have any questions, feel free to contact me at
401-789-2789.

Thank you,
Yours sincerely,
Renuka Nair

1.

Select the one that best describes your company.
1.
2.
3.
4.
5.
6.

2.

For profit health insurance company
Not for profit health insurance company
Health maintenance organization
Mail service prescription company
Pharmacy benefit management company
Federal/State agency

Total number of prescriptions(compounded & non compounded) processed
during the calendar year 1993.
1. 0-50,000
2. 50,000-100,000
3. 100,000-500,000

3.

Total number of subscribers (enrolles & dependents) enrolled under the
drug benefit program during the calendar year 1993.
1.
2.
3.
4.

4.

0-5,000
5,000-10,000
10,000-50,000
50,000-100,000

5. 100,000-500,000
6. 500,000-l,000,000
7. More than 1,000,000

Do you require the pharmacist to differentiate between non compounded
and compounded prescriptions for reimbursement?
1. Yes

5.

4. 500,000-1,000,000
5. More than 1,000,000

2. No

How many drug benefit models do you administer?
Capitation
1.
2.
3.
4.
5.
6.

None

One
Two
Three
Four
More than four
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Fee for service

U& C

Other
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6.

B

lndicate the type of models that reimburse compounded prescriptions.

All models

Some mcx:iels

None

1. None
2. One

3. Two
4. Three
5. Four
6. More than four
7.

For those plans that do not presently reimburse compounded
prescriptions, do you intend reimbursing them in future?
1.
2.
3.
4.

8.

Yes, within the next year
Yes, within the next two years
Yes, after two years
No

Do you have a preapproved list of prescriptions to be compounded?
1. Yes

9.

Are you able to identify when an FDA approved drug is being c
compounded for unapproved uses?
1. Yes

10.

2. No (If no, skip to question 15)

Indicate the person responsible for obtaining preapproval from your
company (CHECK ALL THAT APPLY)
1. Yes

13.

2. No

Do you require that the provider obtain preapproval before he/ she can
compound and receive reimbursement?
1. Yes

12.

2. No

Do you reimburse for FDA approved drugs compounded for unapproved
uses?
1. Yes

11.

2. No

2. No

Check the process for obtaining preapproval
(CHECK ALL THAT APPLY)
1. Prior approval form
2. Approval via computer
3. Approval over computer

4. Approval by fax
5. Other (SPECIFY)

(

55

APPENDIX

(
14.

Indicate the number of hours it takes to obtain approval.
3. Within 48 hours
4. More than 48 hours

1. Immediately
2. Within 24 hours

15.

B

Define the formulas (e.g. EAC + Dispensing fee) of the following types
of reimbursement schemes ..
1. Fee for service

2. Capitation
3. Usual and customary
4. Other (SPECIFY)
16.

Does the reimbursement scheme vary according to the type of
prescriptions? (CHECK ALL THAT APPLY)
1.
2.
3.
4.

17.

Yes, they differ according to the dosage form
Yes, they differ based on the time required for compounding
No
Other (SPECIFY)

Do you conduct Drug Utilization Review on compounded prescriptions?
1. Yes
2. No (IF NO PLEASE ANSWER 17A)
17 A.

Do you intend conducting them in future?
1.
2.
3.
4.

18.

Yes, within the next year
Yes, within the next two years
Yes, after two years
No

What kind of Drug Utilization Review do you conduct?
(CHECK ALL THAT APPLY)
1. Prospective i.e. conducting review before time of dispensing
2. Concurrent i.e. conducting review at time of dispensing
3. Retrospective i.e. conducting review after time of dispensing

19.

Do you conduct Drug l}tilization Review only on the single most costly
ingredient?
1. Yes, only on the-costly ingredient
2. On all the ingredients in the formula
3. Other (SPECIFY)
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Do you allow more than one active ingredient per compounded
prescription?
1. Yes

21.

2. No

Has the number of compounded prescriptions increased over the last two
years? (Skip to question 23)
1. Increased by 0-5%
2. Increased by 6-10%
3. Increased by 11-15%

22.

4. Increased by 16-20%
5. Remained the same
6. Don't know

Has the number of compounded prescriptions decreased over the last two
years?
4. Decreased by 16-20%
5. Remained the same
6. Don't know

1. Decreased by 0-5%
2. Decreased by 6-10%
3. Decreased by 11-15%
23.

What percentage of total prescription dollars constitute compounding?
1. Less than 1%
2. 1%-5%

(
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4. 6%-10%
5. More than 10%

Do you require that all your participating pharmacies compound drugs?
1. Yes, in all the models
2. Yes, in some models
3. No

25.

Do you require that the participating pharmacists provide compounding
services within a reasonable period of time?
1. Yes, within 24 hours

2. Yes, more than 24 hours
3. No

Once again if you have any questions or concerns feel free to contact me at
401-792-2789 or write to me.

PLEASE RETURN IN TIIE ENCLOSED SELF ADDRESSED
PRESTAMPED ENVELOPE

THANK YOU

(

57

OPTIONS LS=80;
PROC FORMAT;
VALUE ABCFMT l='FOR PROFIT HEALTH INSURANCE COMPANY'
2='NOT FOR PROFIT INSURANCE COMPANY'
3='HEALTH MAINTENANCE ORGANIZATION'
4='MAIL SERVICE PRESCRIPTION COMPANY'
5='PHARMACY BENEFIT MANAGEMENT COMPANY'
6='FEDERAL/STATE AGENCY';
VALUE DEFFMT 1='0-50000'
2='50000-100000'
3='100000-500000'
4='500000-1000000'
5='MORE THAN 1000000';
VALUE GHIFMT

1='0-5000'
2='5000-10000'
3='10000-50000'
4='50000-100000'
5='100000-500000'
6='500000-1000000'
7='MORE THAN 1000000';

VALUE JKLFMT l='YES'
2= 'NO I i
VALUE MNO l='NONE'
2='0NE'
3='TW0'
4='THREE'
5='FOUR'
6='MORE THAN FOUR I i
VALUE MNOX l='NONE'
2='0NE'
3='TWO'
4='THREE'
5='FOUR'
6='MORE THAN FOUR I i
VALUE MNOY l='NONE'
2='0NE'
3='TW0'
4='THREE'
5='FOUR'
6='MORE THAN FOUR I i

(

VALUE MNOZ l='NONE'
2='0NE'
3='TWO'
4='THREE'
5='FOUR'
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6='MORE THAN FOUR';
VALUE PQRFMT l='ALL'
2='SOME'
3= 'NONE I;
VALUE PQRXFMT l='ALL'
2='SOME'
3= 'NONE I;
VALUE PQRYFMT l='ALL'
2='SOME'
3= 'NONE I;
VALUE PQRZFMT l='ALL'
2='SOME'
3= 'NONE I;
VALUE STUFMT l='YES NEXT YEAR'
2='YES NEXT 2 YEARS'
3='YES AFTER 2 YEARS'
4='NO'
5='NOT APPLICABLE';
VALUE VWXFMT l='YES'
2= 'NO I;
VALUE YZFMT l='YES'
2= I NO I;
VALUE ABCAFMT l='YES'
2= 'NO I;
VALUE DEFAFMT l='YES'
2= I NO I ;
VALUE GHIAFMT l='PRESCRIBER'
2='PHARMACIST'
3='0THER'
4='NOT APPLICABLE'
5='EITHER PRES OR PHARM';

(

VALUE JKLAFMT Ol='FORM'
02='COMPUTER'
03='PHONE'
04='FAX'
05='0THER'
06='NOT APPLICABLE'
07='FORM+PHONE+FAX'
08='FORM+FAX'
09='PHONE+FAX'
10='FORM+COMPUTER+PHONE'
ll='ALL'
12='FORM+PHONE+FAX'
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13='PHONE+FAX+COMPUTER'
14='COMPUTER+PHONE';

f
\

VALUE MNOAFMT l='IMMEDIATELY'
2='WITHIN 24H'
3='WITHIN 48H'
4='MORE THAN 48H'
5='NOT APPLICABLE';
VALUE PQRAFMT l='FEE FOR SERVICE'
2='CAPITATION'
3='U $ C'
4='0THER'
5='FEE+CAPITATION'
6='FEE+CAP+UC'
7='CAP+UC'
8='FEE+CAP'
9= ALL
I

I;

VALUE STUAFMT l='YES-DOSAGE'
2='YES-TIME'
3='NO'
4='0THER'
5='0N DOSAGE & TIME';
VALUE VWXAFMT l='YES'
2= I NO I ;
VALUE YZAFMT l='YES NEXT YEAR'
2='YES IN NEXT 2 YEARS'
3='YES AFTER 2YRS'
4='NO'
5='NOT APPLICABLE'
6= I DONT KNOW I;
VALUE ABCBFMT

l='PROSPECTIVE'
2='CONCURRENT'
3='RETROSPECTIVE'
4='ALL'
5='CON+RETRO'
6='NOT APPLICABLE'
7='PROS+RETRO'
8= PROS+CON
I

I

;

VALUE ABAFMT l='YES ON COSTLY INGREDIENT'
2='YES ON ALL'
3='0THER'
4='NOT APPLICABLE'
5='EITHER ON COSTLY OR ALL';
VALUE CDAFMT l='YES'
2= 'NO I;

(
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VALUE EFAFMT
(

1='0-5%'
2='6-10%'
3='11-15%'
4='16-20%'
5='REMAINED SAME'
6='DONT KNOW'
7='NOT APPLICABLE'
8= INCREASED
I

VALUE GHAFMT

I;

1='0-5%'
2='6-10%'
3='11-15%'
4='16-20%'
5='REMAINED SAME'
6='DONT KNOW'
7='NOT APPLICABLE'
8= I DECREASED I ;

VALUE IJAFMT l='LESS THAN 1%'
2='1-5%'
3='6-10%'
4='MORE THAN 10%'
5= DONT KNOW
I

VALUE KLAFMT

I

;

l='YES IN ALL'
2='YES IN SOME'
3= I NO I ;

VALUE MNAFMT l='YES IN 24H'
2='YES MORE THAN 24H'
3= 'NO I;
DATA THESIS;
MISSING M;
INPUT ABC 1 DEF 2 GHI 3 JKL 4 MNO 5 MNOX 6 MNOY 7 MNOZ 8
PQR 9 PQRX 10 PQRY 11 PQRZ 12 STU 13 VWX 14 YZ 15 ABCA 16
DEFA 17 GHIA 18 JKLA 19-20 MNOA 21 PQRA 22 STUA 23 VWXA 24
YZA 25 ABCB 26 ABA 27 CDA 28 EFA 29 GHA 30 IJA 31 KLA 32
MNA 33;
IF ABC=l OR ABC=4 OR ABC=5 THEN ABCD=l;
ELSE ABCD=O;
IF 1 LE DEF LE 3 THEN DEFl=l;
ELSE IF 4 LE DEF LE 5 THEN DEFl=O;
IF 1 LE GHI LE 4 THEN GHil=l;
ELSE IF 5 LE GHI LE 7 THEN GHil=O;

(

IF

PQR EQ 1 THEN PQRl=O;
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(

ELSE IF PQR EQ 2 OR 3 THEN PQRl=l;
IF PQRX EQ 1 THEN PQRXl=O;
ELSE IF PQRX EQ 2 OR 3 THEN PQRXl =1;
IF PQRY EQ 1 THEN PQRYl=O;
ELSE IF PQRY EQ 2 OR 3 THEN PQRYl=l;
IF PQRZ EQ 1 THEN PQRZ=O;
ELSE IF PQRZ EQ 2 OR 3 THEN PQRZ=l;
IF MNO EQ 1 THEN PQRX=.;
IF MNOX EQ 1 THEN PQR=.;
IF MNOY EQ 1 THEN PQRY=.;
IF MNOZ EQ 1 THEN PQRZ=.;

IF 1 LE STU LE 3 THEN STUl=l;
(

ELSE IF STU=4 THEN STUl=O;
IF STU=S THEN STU=.;
IF GHIA=4 THEN GHIA=.;
IF JKLA=6 THEN JKLA=.;
IF MNOA=S THEN MNOA=.;
IF 1 LE STUA LE 2 THEN STUAl=O;
ELSE IF STUA=3 THEN STUAl=l;
ELSE IF STUA EQ 4 OR 5 THEN STUAl=O;
IF 1 LE YZA LE 3 THEN YZAl=O;
ELSE IF YZA EQ 4 THEN YZAl=l;
ELSE IF YZA=5 THEN YZA=.;
IF ABA EQ 1 THEN ABAl=O;
ELSE IF 2 LE ABA LE 3 THEN ABAl=l;
ELSE IF ABA EQ 4 THEN ABA=.;
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ELSE IF ABA EQ 5 THEN ABAl=l;
IF 1 LE EFA LE 4 THEN EFAl=O;
ELSE IF 5 LE EFA LE 6 THEN EFAl=l;
ELSE IF EFA=7 THEN EFA=.;
ELSE IF EFA=8 THEN EFAl=O;
IF 1 LE GHA LE 6 THEN EFAl=l;
ELSE IF GHA=7 THEN GHA=.;
ELSE IF GHA=8 THEN EFAl=O;
IF IJA EQ 1 THEN IJAl=l;
ELSE IF 3 LE IJA LE 4 THEN IJAl=O;
ELSE IF IJA EQ 5 THEN IJAl=.;
IF 1 LE KLA LE 2 THEN KLAl=O;
ELSE IF KLA EQ 3 THEN KLAl=l;
(

IF 1 LE MNA LE 2 THEN MNAl=O;
IF ABCB EQ 6 THEN ABCB= . ;
ELSE IF MNA EQ 3 THEN MNAl=l;
FORMAT ABC ABCFMT. DEF DEFFMT. GHI GHIFMT. JKL JKLFMT.
PQR PQRFMT. PQRX PQRXFMT. PQRY PQRYFMT. PQRZ PQRZFMT.
STU STUFMT. VWX VWXFMT. YZ YZFMT. ABCA ABCAFMT.
DEFA DEFAFMT. GHIA GHIAFMT. JKLA JKLAFMT. MNOA MNOAFMT.
PQRA PQRAFMT.
STUA STUAFMT. VWXA VWXAFMT. YZA YZAFMT.
ABCB ABCBFMT.
ABA ABAFMT. CDA CDAFMT. EFA EFAFMT. GHA GHAFMT. IJA IJAFMT.
KLA KLAFMT. MNA MNAFMT.;

(

LABEL ABC='TYPE OF THIRD PARTY'
DEF='TOTAL NUMBER OF PRESCRIPTIONS IN 1993'
GHI='TOTAL NUMBER OF SUBSCRIBERS'
JKL='DIFFERENTIATE BETWEEN THE TWO'
MNO='CAPITATION'
MNOX='FEE FOR SERVICE'
MNOY='U & C'
MNOZ='OTHER'
PQR='FEE FOR SERVICE- MODEL'
PQRX='CAPITATION MODEL'
PQRY='U & C MODEL'
PQRZ='OTHER MODEL'
STU='INTEND REIMBURSING IN FUTURE'
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VWX='PREAPPROVED LIST'
YZ='ABLE TO IDENTIFY UNAPROVED DRUG'
ABCA='REIMBURSE FDA UNAPPROVED DRUG'
DEFA='REQUREMENT FOR PREAPROVAL'
GHIA='PERSON RESPONSIBLE FOR PREAPPROVAL'
JKLA='PROCESS FOR PREAPPROVAL'
MNOA='NUMBER OF HOURS FOR PREAPPROVAL'
PQRA='FORMULA FOR REIMBURSEMENT'
STUA='VARYING SCHEME'
VWXA='DUR'
YZA='INTEND TO CNDUCT DUR IN FUTURE'
ABCB='TYPE OF DUR'
ABA='DUR ON INGREDIENTS'
CDA='NO. OF INGREDIENTS PER COMPOUNDED PRESCRIPTIONS'
EFA='INCREASE IN COMPOUNDED PRESCRIPTIONS'
GHA='DECREASE IN COMPOUNDED PRESCRIPTIONS'
IJA='PERCENTAGE OF TOTAL DOLLARS'
KLA='REQUIREMENT FOR PHARMACIES'
MNA='REASONABLE PERIOD FOR COMPOUNDING';
CARDS;
THE DATA HAS BEEN DELETED TO SAVE SPACE

PROC FORMAT PRINT;
PROC FREQ;
TABLES ABC DEF GHI JKL MNO MNOX MNOY MNOZ PQR PQRX PQRY PQRZ
STU VWX YZ ABCA DEFA GHIA JKLA MNOA STUA VWXA YZA ABCB ABA
CDA EFA GHA IJA KLA MNA;
PROC FREQ;
TABLES(ABCD DEFl GHil IJAl)*JKL/CHISQ;
PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*VWX/CHISQ;
PROC FREQ;
TABLES (ABCD DEFl GHil IJAl)*YZ/CHISQ;
PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*ABCA/CHISQ;
PROC FREQ;
TABLES (ABCD DEFl GHil IJAl)*DEFA/CHISQ;
PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*STUAl/CHISQ;
PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*VWXA/CHISQ;

(

PROC FREQ;
TABLES (ABCD DEFl GHil IJAl)*CDA/CHISQ;
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f

PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*EFAl/CHISQ;
PROC FREQ;
TABLES (ABCD DEFl GHil IJAl)*KLAl/CHISQ;
PROC FREQ;
TABLES (ABCD DE Fl GHil IJAl)*MNAl/CHISQ;
PROC FREQ;
TABLES VWX*DEFA;
PROC FREQ;
TABLES IJA*DEF;
PROC FREQ; TABLES MNO*MNOX*MNOY*MNOZ;

(
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TYPE OF THIRD PARTY

(
ABC

Frequency

FOR PROFIT HEALT
NOT FOR PROFIT I
HEALTH MAINTENAN
MAIL SERVICE PRE
PHARMACY BENEFIT
FEDERAL/STATE AG

8
25
15
6
40
35

Cumulative
Frequency

Percent
6.2
19.4
11. 6
4 .7
31. 0
27.1

Cumulative
Percent
6.2
25.6
37.2
41. 9
72.9
100.0

8
33
48
54
94
129

Frequency Missing

1

TOTAL NUMBER OF PRESCRIPTIONS PROCESSED IN 1993
DEF

Frequency

0-50000
50000-100000
100000-500000
500000-1000000
MORE THAN 100000

12
4
10
21
80

Cumulative
Frequency

Percent
9.4
3.1
7.9
16 . 5
63.0

Cumulative
Percent
9.4
12.6
20 . 5
37.0
100.0

12
16
26
47
127

Frequency Missing

3

TOTAL NUMBER OF SUBSCRIBERS ENROLLED IN 1993
GHI

Frequency

0-5000
5000-10000
10000-50000
50000-100000
100000-500000
500000-1000000
MORE THAN 100000

2
2
7
15
48
25
29

Cumulative
Frequency

Percent
1.6
1.6
5.5
11. 7
37 . 5
19.5
22.7

Cumulative
Percent

2
4
11
26
74
99
128

Frequency Missing

1.6
3.1
8. 6
20.3
57.8
77.3
100.0

2

ABLE TO DIFFERENTIATE BETWEEN COMPOUNDED AND NON COMPOUNDED PRESCRIPTIONS

JKL
YES
NO

Frequency

Percent

106
23

Cumulative
Frequency

82 . 2
17.8
Frequency Missing

(
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106
129

=

1

Cumulative
Percent
82.2
100.0

CAPITATION
MNO

Frequency

1
2
3
4
5
6

Percent

Cumulative
Frequency

72 . 2
4.8
8.7
0.8
2.4
11.1

91
6
11
1
3
14

91
97
108
109
112
126

Cumulative
Percent
72 .2
77.0
85.7
86.5
88.9
100.0

Frequency Missing = 4

FEE FOR SERVICE
MNOX
1
2
3
4
5
6

Frequency

Cumulative
Frequency

Percent
14.3
23.0
7.9
3.2
4.0
47.6

18
29
10
4
5
60

18
47
57
61
66
126

Frequency Missing

(

u
MNOY
1
2
3
4
5
6

Frequency

&

Percent

14.3
37 . 3
45.2
48.4
52.4
100.0

4

c
Cumulative
Frequency

46.8
13.5
9.5
1. 6
1. 6
27.0

59
17
12
2
2
34

Cumulative
Percent

59
76
88
90
92
126

Frequency Missing

Cumulative
Percent
46.8
60.3
69.8
71.4
73.0
100.0

4

REIMBURSE FEE FOR SERVICE- MODEL
PQR
ALL

SOME
NONE

Frequency

Percent

Cumulative
Frequency

93.6
5.5
0.9

102
6
1

Frequency Missing
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102
108
109
21

Cumulative
Percent
93 . 6
99.1
100.0

REIMBURSE CAPITATION MODEL
PQRX

Frequency

ALL
SOME
NONE

Percent

31
5

Cumulative
Frequency

83.8
13 . 5
2.7

1

Cumulative
Percent
83.8
97 . 3
100.0

31
36
37

Frequency Mi ss ing

93

REIMBURSE U & C MODEL

Frequency

PQRY
ALL
SOME
NONE

Percent

Cumulative
Frequency

85 . 5
8.7
5.8

59
6
4

Cumulative
Percent
85.5
94 . 2
100.0

59
65
69

Frequency Missing

61

INTEND REIMBURSING IN FUTURE

STU

Frequency

YES NEXT YEAR
NO

2
4

Percent

Cumulative
Frequency

33.3
66.7

Frequency Missing

Cumulative
Percent

2
6

=

124

PREAPPROVED LIST

vwx
YES
NO

Frequency

Percent

14

10.8
89.2

116

Cumulative
Frequency

Cumulative
Percent

14

10.8
100 . 0

130

ABLE TO IDENTIFY UNAPROVED DRUG

YZ

YES
NO

Frequency

Percent

41
89

(

68

Cumulative
Frequency

31. 5

41

68 . 5

130

Cumulative
Percent
31.5
100 . 0

33.3
100 . 0

(
REIMBURSE FDA UNAPPROVED DRUG USES

ABCA

Frequency

Percent

64
63

YES
NO

Cumulative
Frequency

50 .4
49.6

Cumulative
Percent
50.4
100.0

64
127

Frequency Missing

3

REQUREMENT FOR PREAPROVAL
DEFA

Frequency

YES
NO

Percent

Cumulative
Frequency

17.8
82.2

23
106

cumulative
Percent
17.8
100.0

23
129

Frequency Missing

1

PERSON RESPONSIBLE FOR PREAPPROVAL

(

GHIA
PRESCRIBER
PHARMACIST
EITHER PRES OR P

Frequency
5
11
7

Percent

Cumulative
Frequency
5
16
23

21. 7
47.8
30.4

Frequency Missing

=

Cumulative
Percent
21. 7
69.6
100.0

107

PROCESS FOR PREAPPROVAL

JKLA

Frequency

FORM
COMPUTER
PHONE
FORM+ PHONE+ FAX
FORM+FAX
PHONE+ FAX
FORM+COMPUTER+PH
ALL
PHONE+FAX+COMPUT
COMPUTER+PHONE

2
1
7
4
1
1
3
2
1
1

Percent
8.7
4.3
30.4
17.4
4.3
4.3
13.0
8.7
4.3
4.3

Frequency Missing

69

Cumulative
Frequency
2
3
10
14
15
16
19
21
22
23

= 107

Cumulative
Percent
8.7
13 .0
43.5
60.9
65.2
69.6
82.6
91.3
95.7
100.0

NUMBER OF HOURS FOR PREAPPROVAL
MNOA

Percent

Frequency

IMMEDIATELY
WITHIN 24H
WITHIN 48H

Cumulative
Frequency

43.5
34.8
21 . 7

10
8
5

Frequency Missing

Cumulative
Percent
43 . 5
78 . 3
100.0

10
18
23
107

FACTORS AFFECTING THE REIMBURSEMENT SCHEME
STUA

Frequency

YES-DOSAGE
YES - TIME
NO
OTHER
ON DOSAGE & TIME

Percent

Cumulative
Frequency

4.0
8.0
77.6
4.8
5.6

5
10
97
6
7

Frequency Missing

Cumulative
Percent
4.0
12.0
89.6
94.4
100.0

5
15
112
118
125
5

DUR

VWXA

Frequency

YES
NO

Percent

Cumulative
Frequency

57.4
42.6

74
55

Cumulative
Percent
57.4
100.0

74
129

Frequency Missing

1

INTEND TO CNDUCT DUR IN FUTURE
YZA
YES NEXT YEAR
YES IN NEXT 2 YR
YES AFTER 2YRS
NO
DONT KNOW

Frequency
14
5
2
32
3

Percent
25.0
8.9
3.6
57.1
5.4

Frequency Missing

70

Cumulative
Frequency
14
19
21
53
56
74

Cumulative
Percent
25.0
33.9
37.5
94.6
100.0

TY PE OF DUR

(
ABCB

Frequency

PROSPECTIVE
CONCURRENT
RETROSPECTIVE
ALL
CON+RETRO
PROS+RETRO
PROS+CON

Percent

Cumulative
Frequency

5.5
9.6
30 . 1
26.0
19 . 2
8.2
1. 4

4
7
22
19
14
6
1

Cumulative
Percent
5.5
15.1
4 5. 2
71. 2
90.4
98.6
100.0

4
11
33
52
66
72

73

Frequency Missing

57

DUR ON INGREDIENTS
ABA

Frequency

YES ON COSTLY IN
YES ON ALL
EITHER ON COSTLY

Percent

30
38
5

41.1
52.1
6.8

Frequency Missing

(

Cumulative
Frequency

Cumulative
Percent
41.1
93.2
100.0

30
68
75
57

ALLOW MORE THAN 1 ACTIVE INGREDIENT PER COMPOUNDED PRESCRIPTION
CDA

Frequency

YES
NO

Percent

Cumulative
Frequency

94.5
5.5

121
7

Cumulative
Percent
94.5
100.0

121
128

Frequency Missing

= 2

INCREASE IN COMPOUNDED PRESCRIPTIONS
EFA
0-5%
6-10%
11-15%
16-20%
REMAINED SAME
DONT KNOW
INCREASED

Frequency
19
10
5
2
22
61
2

Percent
15 . 7
8.3
4.1
1. 7
18 . 2
50.4
1.7

Frequency Missing

71

Cumulative
Frequency
19
29
34
36
58
119
121
9

Cumulative
Percent
15 . 7
24.0
28.1
29 . 8
47.9
98 . 3
100.0

DECREASE IN COMPOUNDED PRESCRIPTIONS

(
GHA

Frequency

0-5%
6-10%
16-20%
REMAINED SAME
DONT KNOW

Cumulative
Frequency

Percent
6.6
1.1
2.2
23.1
67 . 0

6
1
2
21
61

Cumulative
Percent
6.6
7.7
9.9
33.0
100.0

6
7
9
30
91

Frequency Missing

39

PERCENTAGE OF COMPOUNDED PRESCRIPTIONS IN TERMS OF TOTAL DOLLAR SALES

IJA
LESS THAN 1%
1-5%
6-10%
DONT KNOW

Frequency

Cumulative
Frequency

Percent
66.4
24.0
1. 6
8.0

83
30
2
10

Cumulative
Percent
66.4
90 . 4
92.0
100.0

83
113
115
125

Frequency Missing

5

REQUIREMENT PHARMACIES TO COMPOUND PRESCRIPTIONS
Frequency

KLA
YES IN ALL
YES IN SOME
NO

Percent

Cumulative
Frequency

34 . 6
1.5
63 . 8

45
2
83

Cumulative
Percent
34.6
36 . 2
100.0

45
47
130

REQUIRE PHARMACIES TO COMPOUND WITHIN REASONABLE TIME PERIOD
MNA
YES IN 24H
YES MORE THAN 24
NO

Frequency
28
5

97

72

Percent
21 . 5
3.8
74.6

Cumulative
Frequency
28
33
130

Cumulative
Percent
21 . 5
25.4
100.0

(
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